Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Provider
European Journal of Cancer
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
Nature
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
Nature Reviews. Clinical Oncology
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Annals of Oncology
Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors
New England Journal of Medicine
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Targeted Oncology
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
The Oncologist
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Esmo Open
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
Esmo Open
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma